MicrofluidX announces a joint research project with Immatics to combine Immatics’ manufacturing of TCR-T cells with MicrofluidX’s innovative new platform, the Cyto Engine™.
MicrofluidX and Immatics will collaborate to investigate more efficient and cost-effective manufacturing solutions for Cell and Gene Therapies.
By utilising the Cyto Engine’s precision process control, closed system automation, online and inline analytics and end-to-end capabilities, manufacturing processes can become more efficient, with shorter culturing times and significant reduction in the labour required to produce these complex therapies.
Early trials in the MicrofluidX bioreactors have already demonstrated better transduction efficiencies of primary T cells (5x higher) and associated reduction in vector consumption (10x lower) than conventional approaches.
“We are excited to be working with such an experienced partner in the field of TCR-Ts, as we progress the Cyto Engine’s development. We look forward to bringing the power of the Cyto Engine to the Immatics process and proving out the process improvements that precision control can bring”, says Antoine Espinet, CEO at MicrofluidX.
“We are excited to test the abilities of the Cyto Engine platform within our cell therapy manufacturing process. The ability to precisely control T cell manufacturing via a microfluidic architecture represents an innovative approach to adoptive cell therapy production”, says Amir Alpert, Director Technology Scouting & Development.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy